Abstract
We report the usefulness of a 3.4-kb mitochondrial genome deletion (3.4mtδ) for molecular definition of benign, malignant, and proximal to malignant (PTM) prostate needle biopsy specimens. The 3.4mtδwas identified through long-extension polymerase chain reaction (PCR) analysis of frozen prostate cancer samples. A quantitative PCR assay was developed to measure the levels of the 3.4mtδin clinical samples. For normalization, amplifications of a nuclear target and total mitochondrial DNA were included. Cycle threshold data from these targets were used to calculate a score for each biopsy sample. In a pilot study of 38 benign, 29 malignant, and 41 PTM biopsy specimens, the difference between benign and malignant core biopsy specimens was well differentiated (P < .0001), with PTM indistinguishable from malignant samples (P = .833). Results of a larger study were identical. In comparison with histopathologic examination for benign and malignant samples, the sensitivity and specificity were 80% and 71%, respectively, and the area under a receiver operating characteristic (ROC) curve was 0.83 for the deletion. In a blinded external validation study, the sensitivity and specificity were 83% and 79%, and the area under the ROC curve was 0.87. The 3.4mtδmay be useful in defining malignant, benign, and PTM prostate tissues.
Original language | English (US) |
---|---|
Pages (from-to) | 57-66 |
Number of pages | 10 |
Journal | American journal of clinical pathology |
Volume | 129 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2008 |
Keywords
- False-negative biopsy result
- Field cancerization
- MtDNA deletion
- Prostate biopsy
- Sensitivity
- Specificity